Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $316.6 million.

  • Taysha Gene Therapies' Liabilities and Shareholders Equity rose 7565.16% to $316.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $948.6 million, marking a year-over-year increase of 3429.95%. This contributed to the annual value of $160.4 million for FY2024, which is 715.97% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Liabilities and Shareholders Equity is $316.6 million, which was up 7565.16% from $333.3 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Liabilities and Shareholders Equity peaked at $333.3 million during Q2 2025, and registered a low of $81.5 million during Q2 2023.
  • Moreover, its 4-year median value for Liabilities and Shareholders Equity was $160.4 million (2024), whereas its average is $172.0 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Liabilities and Shareholders Equity tumbled by 4270.93% in 2023, and later skyrocketed by 14575.13% in 2024.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Liabilities and Shareholders Equity stood at $126.3 million in 2022, then soared by 36.79% to $172.7 million in 2023, then fell by 7.16% to $160.4 million in 2024, then surged by 97.4% to $316.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $316.6 million in Q3 2025, compared to $333.3 million in Q2 2025 and $138.4 million in Q1 2025.